Two patients with amyotrophic lateral sclerosis (ALS) have received stem cell injections to their spinal cords at UMHS – the first two to receive the experimental injections in Michigan as part of a national clinical trial.
For nearly two years, U-M neurologist Eva Feldman, M.D., Ph.D. has led the nation’s first clinical trial of stem cell injections in patients with the deadly degenerative disease known as amyotrophic lateral sclerosis, often called ALS or Lou Gehrig’s disease. Now, a new approval from the FDA paves the way for U-M to become the second site in the trial,
The first published results from an early-stage clinical trial show that spinal cord stem cells can be delivered safely into the spines of patients with the condition commonly known as Lou Gehrig's disease, opening the door for further research on this innovative approach.
Physician-scientists worldwide will vie for the newly-established $100,000 annual Taubman Prize for Excellence in Translational Medical Science starting in 2012, the A. Alfred Taubman Medical Research Institute has announced.